Leuven, Belgium, 14 September 2020 - 8.00 A.M. CET - Oxurion NV (Euronext Bxls: OXUR), a biopharmaceutical company developing next-generation standard-of-care therapies for diabetic macular edema (DME), announces today that the Company's CEO, Dr. Patrik De Haes, will be presenting at HC Wainwright & Co's 22nd Annual Global Investment Conference on Wednesday, September 16th, 2020 at 10:00 a.m. ET.

The presentation will cover Oxurion's emerging DME franchise designed to improve the treatment outcomes of all DME patients. The Company's franchise is based around THR-149 and THR-687, two novel drug candidates with different, non-VGEF modes of action. DME is a significant global healthcare problem and the major cause of vision loss in diabetic patients worldwide.

During the virtual conference, which will take place September 14-16, 2020, Oxurion will also be participating in one-on-one sessions.

Attachments

  • Original document
  • Permalink

Disclaimer

Oxurion NV published this content on 14 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2020 06:34:02 UTC